Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication

 
• By Alaric DeArment
  
BMS will continue a Phase III pivotal trial of Opdivo in first-line bladder cancer after a primary endpoint setback • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas